BioArctic partner Eisai to present new lecanemab clinical data at CTAD

BioArctic’s partner, Eisai, is set to present fresh clinical findings and real-world evidence regarding the Alzheimer's treatment lecanemab. The data will be unveiled during the Clinical Trials on Alzheimer's Disease (CTAD) conference, scheduled to take place in Boston from November 16 to 19, 2026.

The presentations are expected to highlight the long-term efficacy and safety profile of the drug, which targets amyloid-beta plaques in the brain. By incorporating real-world data alongside clinical trial results, the company aims to demonstrate how the treatment performs in broader, less controlled patient populations.

As the medical community continues to assess the role of amyloid-targeting therapies, this data release serves as a benchmark for ongoing clinical adoption. These findings will likely influence upcoming discussions on standardized care protocols for Alzheimer’s patients globally.